ÂÜÀòÂÒÂ×

Dr. Kabakibi has over two decades of experience in drug discovery and early development in large pharma and biotech companies. He took several projects, across multiple therapeutic areas, from concept through to clinical development. Most recently, he co-founded Tollnine Inc., an immuno-oncology company developing novel antibody conjugates and served as its Vice President of Biology. Prior to that, he was the Executive Director of Biology at Solstice Biologics, an RNAi and immuno-oncology company exploring novel siRNA technologies for the development of human therapeutics. Before Solstice, Dr. Kabakibi was the Head of Biology and Pharmacology at Traversa Therapeutics. Prior to Traversa, he spent 5 years at Kalypsys Inc. as the Head of Pharmacology. He started his career at Pfizer working on inflammation and metabolic disease targets.

Dr. Kabakibi earned his Ph.D. in Biochemistry from the University of Massachusetts, Lowell and performed his graduate research at the Massachusetts General Hospital, Harvard Medical School. He earned a Master’s Degree (M.Sc.) in Medical Laboratory Sciences from Northeastern University.